Results 201 to 210 of about 788,644 (353)

Humans are not unique: difficult birth is common in placental mammals

open access: yesBiological Reviews, EarlyView.
ABSTRACT Human childbirth is widely presumed to be uniquely difficult and dangerous compared to birth in other mammals. Tight fetopelvic proportions can result in obstructed labour and contribute to high rates of maternal and neonatal mortality. Ideas summarised under the ‘obstetrical dilemma’ have contributed to this assumption by explaining difficult
Nicole D. S. Grunstra
wiley   +1 more source

Use of microsurfaced acellular dermal matrix for the generation of site‐appropriate keratinized tissue in soft tissue augmentation healing: Proof of concept

open access: yesClinical Advances in Periodontics, EarlyView.
Abstract Background Autogenous grafts remain the gold standard for soft tissue augmentation, but allogeneic dermal matrices (ADMs) offer a viable alternative. Limited cellular infiltration and neovascularization restrict ADM efficacy; this study investigates a novel microsurfaced ADM (MS‐ADM) designed to address these limitations. Methods This 180‐day,
Michael K. McGuire   +4 more
wiley   +1 more source

Initial productive and latent HIV infections originate in vivo by infection of resting T cells. [PDF]

open access: yesJ Clin Invest, 2023
Wietgrefe SW   +31 more
europepmc   +1 more source

Sero - Epidemiology of Hepatitis E and D Infections among HIV - Infected and HIV/HCV - Coinfected Patients in Jahrom, Southern Iran

open access: diamond, 2018
Enayatollah Shadmand   +6 more
openalex   +2 more sources

Living Microbial Drugs

open access: yesChemistry – A European Journal, EarlyView.
The introduction outlines the review scope. Microbial cell factories as living drugs cover host–gut microbiota, bacteria, yeast, and other microbial systems, with comparative host advantages. Engineering strategies include synthetic circuits, quorum sensing, and memory.
Cemile Elif Özçelik   +3 more
wiley   +1 more source

Case study of PEPFAR funding cuts on HIV infections and deaths: reversing hard-won gains. [PDF]

open access: yesAIDS
Apollo T   +13 more
europepmc   +1 more source

Serious Infection in Crohn's Disease Patients Treated With Ustekinumab: US Food and Drug Administration Active Postmarket Risk Identification and Analysis in the Sentinel Initiative

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
The U.S. Food and Drug Administration (FDA) used an Active Postmarket Risk Identification and Analysis (ARIA) system to address a safety issue (serious infection) identified during clinical review of an application to market ustekinumab as a treatment for Crohn's disease (CD). FDA used an active‐comparator new‐user cohort design, data from six Sentinel
Joel L. Weissfeld   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy